ClinicalTrials.gg
Active, not recruitingNCT04882098APEXUpdated Nov 4, 2026Results posted

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 280 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 4, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,054
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
Largest of 14
1,054 · median 173
Started
2021
with 3 others
Phase 3
7 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one has the largest enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 5th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have active psoriatic arthritis (PsA) despite previous non-biologic disease-modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
  • Have a diagnosis of PsA for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by: at least 3 swollen joints and 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory
  • Have >= 2 joints with erosions on baseline radiographs of the hands and feet as determined by central read
  • Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeter (cm) diameter or nail changes consistent with psoriasis

Exclusion criteria

Exclusion Criteria:

  • Has known allergies, , or intolerance to study intervention or its
  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (AS)/non-radiographic axial spondyloarthritis (nr-axSpA), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other Janus kinase (JAK) inhibitor
  • Has received any systemic (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,054 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab and Placebo

    Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.

    Drug: Guselkumab

  • Experimental
    Group 3: Placebo Followed by Guselkumab

    Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Participants will receive guselkumab as SC injection.

    Also known as: CNTO 1959

  • DrugPlacebo

    Participants will receive matching placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

    ACR 20 response: \>=20% improvement from baseline (bl) in both swollen (66 joints), tender (68 joints) joint count, \>=20% improvement from bl in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100mm, 0=no pain, 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100mm, 0=excellent, 100=poor), physician's global assessment of disease activity (VAS; 0-100mm, 0=no arthritis activity,100=extremely active arthritis), HAQ-DI (questionnaire assessing 8 functional areas; 0-3, 0=no difficulty, 3=inability to perform task in area), and CRP. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Composite-discontinue study drug not due to ND/MD, initiate/increase DMARD/oral corticosteroid, initiate prohibited PsA treatment; Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD.

    Time frame: At Week 24

Secondary outcomes

  1. Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24

    Modified vdH-S score was sum of erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score was total erosion severity in 40 joints of 2 hands and 12 joints of 2 feet, maximum erosion score=320. Each hand joint was scored on 0 to 5 with 0 =no erosion, 5 =complete collapse of bone. Foot joint was scored on 0 to 10, 0 =no erosion, 10 =complete collapse of bone. JSN score was total JSN score in same 52 joints, each joint scored on 0 to 4 with 0 indicating no JSN, and 4 indicating absence of joint space, maximum JSN score=208. Maximum modified vdH-S score=528. Higher score =severe structural destruction and complete loss of joint spaces. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD

    Time frame: Baseline (after first administration of study drug) and Week 24

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  3. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  4. Number of Participants With Reasonably Related Adverse Events (AEs)

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  5. Number of Participants With TEAEs Leading to Discontinuation of Study Intervention

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  6. Number of Participants With Treatment Emergent Infections

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  7. Number of Participants With Injection-site Reactions Leading to Discontinuation of Study Intervention

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  8. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  9. Number of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Toxicity Grade Laboratory Values

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  10. Serum Guselkumab Concentration

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

  11. Number of Participants With Anti-guselkumab Antibodies

    Time frame: From baseline (after first administration of study drug) up to 168 weeks

07

Results

Posted Feb 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by Guselkumab
Started388280386
Modified full analysis set371273376
Completed370270372
Not completed181014
Withdrew: Adverse event721
Withdrew: Death010
Withdrew: Lack of efficacy233
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject619
Withdrew: Subject refused further study treatment100
Withdrew: Other221

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR 20 response: \>=20% improvement from baseline (bl) in both swollen (66 joints), tender (68 joints) joint count, \>=20% improvement from bl in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100mm, 0=no pain, 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100mm, 0=excellent, 100=poor), physician's global assessment of disease activity (VAS; 0-100mm, 0=no arthritis activity,100=extremely active arthritis), HAQ-DI (questionnaire assessing 8 functional areas; 0-3, 0=no difficulty, 3=inability to perform task in area), and CRP. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Composite-discontinue study drug not due to ND/MD, initiate/increase DMARD/oral corticosteroid, initiate prohibited PsA treatment; Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
percentage of participantsGroup 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by Guselkumab
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 2468.366.647.0
Statistical analysis
  • Group 1: Guselkumab 100 mg q8w vs Group 3: Placebo Followed by Guselkumab · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage: 21.3 · 95% CI 14.4 to 28.2
  • Group 2: Guselkumab 100 mg q4w vs Group 3: Placebo Followed by Guselkumab · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage: 19.7 · 95% CI 12.1 to 27.2
SecondaryChange From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24

Modified vdH-S score was sum of erosion score (hand, feet) and joint space narrowing (JSN) score (hand, feet). Joint erosion score was total erosion severity in 40 joints of 2 hands and 12 joints of 2 feet, maximum erosion score=320. Each hand joint was scored on 0 to 5 with 0 =no erosion, 5 =complete collapse of bone. Foot joint was scored on 0 to 10, 0 =no erosion, 10 =complete collapse of bone. JSN score was total JSN score in same 52 joints, each joint scored on 0 to 4 with 0 indicating no JSN, and 4 indicating absence of joint space, maximum JSN score=208. Maximum modified vdH-S score=528. Higher score =severe structural destruction and complete loss of joint spaces. Natural Disaster (ND)-site inaccessible due to COVID-19. Major Disruption (MD)-disruption involving Ukraine and neighboring countries/territories. Intercurrent event (ICE) handling: Hypothetical-discontinue/severe noncompliance of study drug due to ND/MD

Time frame:
Baseline (after first administration of study drug) and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 24
Score on a scaleGroup 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by Guselkumab
Change From Baseline in Psoriatic Arthritis (PsA) Modified Van Der Heijde-Sharp (vdH-S) Total Score at Week 240.54 (0.14 to 0.95)0.55 (0.10 to 1.00)1.35 (0.94 to 1.75)
Statistical analysis
  • Group 1: Guselkumab 100 mg q8w vs Group 3: Placebo Followed by Guselkumab · ANCOVA · p = <0.001 · Least square mean difference: -0.8 · 95% CI -1.28 to -0.33
  • Group 2: Guselkumab 100 mg q4w vs Group 3: Placebo Followed by Guselkumab · ANCOVA · p = =0.002 · Least square mean difference: -0.8 · 95% CI -1.31 to -0.28
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Serious Adverse Events (SAEs)
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Reasonably Related Adverse Events (AEs)
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs Leading to Discontinuation of Study Intervention
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Infections
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Injection-site Reactions Leading to Discontinuation of Study Intervention
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Abnormalities
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Toxicity Grade Laboratory Values
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondarySerum Guselkumab Concentration
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-guselkumab Antibodies
Time frame:
From baseline (after first administration of study drug) up to 168 weeks

Results for this outcome have not been posted.

Adverse events

Collected over All cause mortality, SAEs, and non-SAEs: From baseline (after first administration of study drug) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Guselkumab 100 mg q8w0/388 (0%)12/388 (3.1%)41/388 (10.6%)
Group 2: Guselkumab 100 mg q4w1/280 (0.4%)5/280 (1.8%)22/280 (7.9%)
Group 3: Placebo Followed by Guselkumab0/386 (0%)10/386 (2.6%)42/386 (10.9%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventGroup 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by Guselkumab
PneumoniaInfections and infestations2/3880/2800/386
Covid-19Infections and infestations1/3881/2801/386
DiverticulitisInfections and infestations0/3881/2800/386
Tendon RuptureInjury, poisoning and procedural complications0/3881/2800/386
EndometriosisReproductive system and breast disorders0/3881/2800/386
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/3881/2800/386
Atrial FibrillationCardiac disorders0/3880/2801/386
CholelithiasisHepatobiliary disorders0/3880/2801/386
Clavicle FractureInjury, poisoning and procedural complications0/3880/2801/386
Humerus FractureInjury, poisoning and procedural complications0/3880/2801/386
Most frequent other events
Most frequent other events
EventGroup 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by Guselkumab
Upper Respiratory Tract InfectionInfections and infestations20/38815/28022/386
Covid-19Infections and infestations22/3888/28020/386

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
Mean52.9 ± 13.0352.3 ± 13.1553.4 ± 12.9252.9 ± 13.02
Age, Customized
Age, Customized(Participants)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
Adults (18-64 years)311229304844
From 65 to 84 years775182210
85 years and over0000
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
Female182127170479
Male206153216575
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
Hispanic or Latino64818
Not Hispanic or Latino3822763781036
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
American Indian or Alaska Native0022
Asian613861160
Native Hawaiian or Other Pacific Islander2204
Black or African American2002
White322240321883
More than one race0011
Unknown or Not Reported1012
Region of Enrollment
Region of Enrollment(Participants)Group 1: Guselkumab 100 mg q8wGroup 2: Guselkumab 100 mg q4wGroup 3: Placebo Followed by GuselkumabTotal
Australia3339
Bosnia and Herzegovina24132562
Bulgaria32283595
Canada3115
China25172769
Croatia82515
Estonia32510
Georgia373033100
Germany4105
Greece1012
Hungary5101025
Israel62715
Italy3227
Latvia134421
Lithuania16152354
Malaysia42511
Philippines32182373
Poland38252790
Russian Federation20161955
Serbia27202875
Slovakia66618
Slovenia1102
Korea, South0011
Spain991432
Taiwan1135
Turkey1012
Ukraine35253999
United States10111334
Czech Republic21162663
08

Study locations

280 sites

Showing the first 100 of 280 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ritchlin CT, Coates LC, Mease PJ, van der Heijde D, Song J, Jiang Y, Shawi M, Kollmeier AP, Rahman P. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2023 Jan 10;24(1):22. doi: 10.1186/s13063-022-06945-y. PubMed 36627711 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2024, 42 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 42 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 11, 2021
StartActual
Jun 17, 2021
Primary completionActual
Dec 30, 2024
CompletionEst.
Oct 6, 2027
Results first posted
Feb 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • A.O.U. Città della Salute e della Scienza · Foligno, Italy
Show 1 removed
  • A.O.U. Città della Salute e della Scienza · Torino, Italy
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • A.O.U. Città della Salute e della Scienza · Foligno, Italy
    Show 1 removed
    • A.O.U. Città della Salute e della Scienza · Torino, Italy
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04882098
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Jun 17, 2021
Primary completion
Dec 30, 2024
Completion
Oct 6, 2027 (estimated)
Results posted
Feb 4, 2026
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion